Clinical trial
Trial of Lamivudine Treatment in HBeAg Negative Chronic Hepatitis B Patients (in…
NCT00338780 · Chinese University of Hong Kong, Other · Completed
Key facts
| NCT number | NCT00338780 |
|---|---|
| Title | Trial of Lamivudine Treatment in HBeAg Negative Chronic Hepatitis B Patients (in Asia) |
| Official title | A Randomised, Double-Blinded, Placebo-Controlled Trial of Lamivudine Treatment in HBeAg Negative Chronic Hepatitis B Patients (in Asia) |
| Lead sponsor | Chinese University of Hong Kong, Other |
| Collaborators | GlaxoSmithKline Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Chronic Hepatitis B |
| Intervention type | Drug |
| Interventions | Lamivudine/ Placebo 100mg daily |
| Start date | Nov 1, 2000 |
| Completion | Jan 1, 2005 |
| First posted | Jun 20, 2006 |
| Last update posted | Oct 30, 2006 |
| Countries | China |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: